ADA 2024

Jun 27, 2024

Type 1 Diabetes (T1D) arises from the autoimmune destruction of insulin-producing islet cells in the pancreas. This destruction results in a complete loss of insulin production, leading to significant impairment in blood glucose control. Without insulin, the body cannot properly process nutrients, causing persisten...

Jun 27, 2024

Obesity, a chronic disease linked to increased risks of complications and mortality, has spurred significant research into the mechanisms of weight regulation and the gut-brain axis's role in appetite control. This understanding has paved the way for the development of safe and effective treatments, such as glucago...

Jun 27, 2024

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications used to treat type 2 diabetes mellitus (T2DM) and obesity by lowering serum glucose levels and managing metabolism in affected patients. Companies are continuously striving to improve approved therapies and develop next-generation obesity ...

Jun 27, 2024

The American Diabetes Association (ADA), a premier voluntary health organization, has been at the forefront of combating the diabetes epidemic and enhancing the lives of individuals with diabetes for 83 years. The ADA has consistently fueled discovery and research aimed at treating, managing, and preventing diabete...